Antbody fusion protein and related compositions for targeting cancer
AssigneeDignity Health
InventorsRachael Sirianni, Rebecca Cook, Tsafrir MOR
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell. Also disclosed herein are methods of treating cancer in a subject, comprising: providing a composition comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell; and treating the cancer by administering a therapeutically effective dosage of the composition to the subject.
Claims25
A composition comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell, and
- wherein the composition includes a sequence with at least 80% sequence identity to SEQ ID NO:
- 9.
(canceled)
(canceled)
(canceled)
(canceled)
22-50. (canceled)
A method of treating cancer in a subject, comprising:
- providing a composition comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell,
- wherein the composition includes a sequence with at least 80% sequence identity to SEQ ID NO:
- 9;
- and
- treating the cancer by administering a therapeutically effective dosage of the composition to the subject.
A composition, comprising:
- a polypeptide with at least two domains,
- wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell;
- and
- comprising a sequence as set forth in SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, or SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.